Hey, this is Stocks_Pedia.
Here I would like to introduce you to some unfamiliar companies that you may probably haven't heard of, and hope it can be of some help to your investments.
The company I'm going to introduce this time is $Vericel(VCEL)$.
It went public on 4th February 1997.
[Company Profile]
Founded in 1989, Vericel Corporation is a regenerative medicine company that focuses on the development of innovative cellular therapies to repair or regenerate damaged or diseased tissue.
The company is developing multi-cellular therapies for the treatment of specific patients with severe, chronic ischaemic cardiovascular disease. The company sees ixmyelocel-T as a multifunctional disease-modifying therapy that includes tissue reconstruction, immunomodulation and promotion of angiogenesis.
[History & Events]
1989: The company was formed in Ann Arbor, Michigan.
1995: The company acquired BioSurface Technologies.
2012: The company raised $40,000,000 / Post Ipo Equity from Eastern Capital.
2014: The company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.
2015: The company announced Long-Term Supply Agreement With Matricel for Key Component of MACI™.
2016: The company developed the MACI which was approved by the FDA.
2018: The company raised $74,800,000 / Post Ipo Equity.
2022: The company announced Appointment of Jonathan Siegal as Principal Accounting Officer.
[Main Business Segments]
[Net Income & Total Revenue]
[Competitors]
Neuro-Bio
Inheritor Cell Technology
Fratagene Therapeutics
Orbsen Therapeutics
Comments